VMAT2
6 drugs CNS
3
approved indications
6
Approved Drugs
3
Companies
3
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (3 companies)
✓ All 6 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (3 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Teva 3 drugs
NEUROCRINE 2 drugs
BAUSCH 1 drug
By Therapeutic Area
CNS 6 drugs
Drugs by Company PRO
Teva 3 drugs
NEUROCRINE 2 drugs
BAUSCH 1 drug
By Therapeutic Area
CNS 6 drugs
AUSTEDO, AUSTEDO XR, INGREZZA SPRINKLE, INGREZZA +2 more
Indications Treated
Huntington's DiseaseChoreaTardive Dyskinesia
All Drugs Targeting VMAT2
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| AUSTEDO | Teva | 2017 | 3 | CNS |
| AUSTEDO XR | Teva | 2023 | 3 | CNS |
| INGREZZA SPRINKLE | NEUROCRINE | 2024 | 3 | CNS |
| INGREZZA | NEUROCRINE | 2017 | 2 | CNS |
| XENAZINE | BAUSCH | 2008 | 2 | CNS |
| TETRABENAZINE | Teva | 2015 | 1 | CNS |